Fast and Secure Delivery Worldwide Express & Expedited Shipping Service
USD $1968.36
IndiaPrevymis (Letermovir) is an antiviral medication specifically designed to prevent cytomegalovirus (CMV) infection in adults undergoing allogeneic hematopoietic stem cell transplantation (HSCT). This innovative treatment is crucial for patients with weakened immune systems, helping to reduce the risk of CMV reactivation and associated complications.
Letermovir works by inhibiting the replication of CMV. It targets the viral terminase complex, which is essential for the virus to replicate and spread. By blocking this process, Prevymis effectively reduces the viral load in patients, promoting better health outcomes during the post-transplant period.
Prevymis is indicated for the prophylaxis of CMV infection and disease in adult patients who are at high risk following HSCT. It is particularly beneficial for those who are CMV-seropositive and receiving transplants from CMV-seronegative donors.
The recommended dosage of Prevymis is typically 480 mg once daily, starting on the day of transplantation and continuing for at least 100 days post-transplant. It is important to follow the healthcare provider's instructions regarding dosage and duration.
Common side effects of Prevymis may include nausea, diarrhea, headache, and fatigue. Patients should report any severe or persistent side effects to their healthcare provider. Regular monitoring may be necessary to manage any adverse reactions effectively.
Prevymis may interact with other medications, so it is important for patients to inform their healthcare provider about all drugs they are currently taking, including over-the-counter medications and supplements.
Prevymis (Letermovir) represents a significant advancement in the prevention of CMV infection for patients undergoing HSCT. By understanding its mechanism, indications, and administration guidelines, patients and healthcare providers can work together to optimize treatment outcomes and enhance recovery.
